Precision Diabetes, Inc. (PDI) Presents Knowledge on Precision IGT Prediabetes Check at Precision Diabetes Drugs 2021 Convention | Nationwide Information

0
341

RALEIGH, NC, April 15, 2021 / PRNewswire / – Precision Diabetes, Inc. (PDI), an emerging leader in precision diabetes diagnostics, announced results of a study on its precision IGT prediabetes at Precision Diabetes Medicine 2021 Conference, Precision Medicine’s annual research symposium -Test known in Diabetes Initiative (PMDI) – a joint effort of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

The study “Serum Alpha-Hydroxybutyrate (AHB) Predicts Elevated 1-Hour Glucose Levels in Normoglycemic Patients” was designed to assess the predictive value of AHB for impaired glucose tolerance as measured by the 1-Hour Oral Glucose Tolerance Test (OGTT). . Using a proprietary algorithm that includes AHB and predicts 1-hour glucose levels greater than 155 mg / dL, Precision IGT was able to strongly predict abnormalities in glucose regulation even after known risk factors such as fasting glucose, HbA1c, age, gender, and BMI. The data also showed that Precision IGT predicted impaired early insulin response during the 1-hour OGTT, even in patients with normal fasting glucose and HbA1c levels.

Early diagnosis and treatment can prevent or delay the progression of prediabetes or early-stage diabetes. Unfortunately, tests like HbA1c and fasting glucose alone cannot diagnose up to 40% of people who have impaired glucose tolerance (IGT) due to the infrequently used oral glucose tolerance test (OGTT). While the OGTT has been considered the standard for predicting diabetes risk, it is not widely used in clinical practice due to the logistical difficulty of the procedure, which can take up to three hours to administer. Precision IGT, measured as part of a routine blood draw, could be a valuable clinical replacement for the oral glucose tolerance test (OGTT).

In addition, accumulating evidence suggests that the 1-hour glucose level measured by the OGTT is a stronger predictor of future type 2 diabetes than the 2-hour level and is significantly associated with diabetes complications and mortality. It has been suggested that 1-hour glucose, as a replacement for 2-hour glucose, be considered the preferred marker for IGT.

PDI is also pleased to announce the purchase of a key patent relevant to these results from the True Health Liquidating Trust (THLT). THLT has been prepared under the confirmed liquidation plan for the insolvency cases of THG Holdings and related debtors, including True Health Diagnostics. The granted patent covers the use of alpha-hydroxybutyrate (AHB) to detect 1-hour glucose levels as measured by the OGTT.

About Precision Diabetes, Inc.

Precision Diabetes, Inc. (Raleigh, North Carolina) is an emerging leader in enabling precision medicine for diabetes using novel diabetes biomarkers and algorithms. The company’s mission is to revolutionize the diagnostic assessment of diabetes by providing a spectrum of unique diabetes tests that span the risk of developing diabetes to developing diabetes complications. Precision Diabetes is the exclusive US provider of the GlycoMark® test. Europe, Australia, the Asia-Pacific region, the middle Eastand Mexico. More information is available at www.precisiondiabetesinc.com.

Media contact:

Jacqueline Madejczyk

Precision Diabetes, Inc.

919-480-0754

jmadejczyk@precisiondiabetesinc.com

View the original content to download multimedia: http://www.prnewswire.com/news-releases/precision-diabetes-inc-pdi-present-data-on-precision-igt-prediabetes-test-at-precision- diabetes-medicine -2021-conference-301269406.html

SOURCE Precision Diabetes, Inc.